Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
HIV Seropositivity: HELP
Articles by Anonymous2010731
Based on 1 article published since 2008
||||

Between 2008 and 2019, Anonymous2010731 wrote the following article about HIV Seropositivity.
 
+ Citations + Abstracts
1 Clinical Trial Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. 2012

Thigpen, Michael C / Kebaabetswe, Poloko M / Paxton, Lynn A / Smith, Dawn K / Rose, Charles E / Segolodi, Tebogo M / Henderson, Faith L / Pathak, Sonal R / Soud, Fatma A / Chillag, Kata L / Mutanhaurwa, Rodreck / Chirwa, Lovemore Ian / Kasonde, Michael / Abebe, Daniel / Buliva, Evans / Gvetadze, Roman J / Johnson, Sandra / Sukalac, Thom / Thomas, Vasavi T / Hart, Clyde / Johnson, Jeffrey A / Malotte, C Kevin / Hendrix, Craig W / Brooks, John T / Anonymous2010731. ·Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, USA. mthigpen@cdc.gov ·N Engl J Med · Pubmed #22784038.

ABSTRACT: BACKGROUND: Preexposure prophylaxis with antiretroviral agents has been shown to reduce the transmission of human immunodeficiency virus (HIV) among men who have sex with men; however, the efficacy among heterosexuals is uncertain. METHODS: We randomly assigned HIV-seronegative men and women to receive either tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or matching placebo once daily. Monthly study visits were scheduled, and participants received a comprehensive package of prevention services, including HIV testing, counseling on adherence to medication, management of sexually transmitted infections, monitoring for adverse events, and individualized counseling on risk reduction; bone mineral density testing was performed semiannually in a subgroup of participants. RESULTS: A total of 1219 men and women underwent randomization (45.7% women) and were followed for 1563 person-years (median, 1.1 years; maximum, 3.7 years). Because of low retention and logistic limitations, we concluded the study early and followed enrolled participants through an orderly study closure rather than expanding enrollment. The TDF-FTC group had higher rates of nausea (18.5% vs. 7.1%, P<0.001), vomiting (11.3% vs. 7.1%, P=0.008), and dizziness (15.1% vs. 11.0%, P=0.03) than the placebo group, but the rates of serious adverse events were similar (P=0.90). Participants who received TDF-FTC, as compared with those who received placebo, had a significant decline in bone mineral density. K65R, M184V, and A62V resistance mutations developed in 1 participant in the TDF-FTC group who had had an unrecognized acute HIV infection at enrollment. In a modified intention-to-treat analysis that included the 33 participants who became infected during the study (9 in the TDF-FTC group and 24 in the placebo group; 1.2 and 3.1 infections per 100 person-years, respectively), the efficacy of TDF-FTC was 62.2% (95% confidence interval, 21.5 to 83.4; P=0.03). CONCLUSIONS: Daily TDF-FTC prophylaxis prevented HIV infection in sexually active heterosexual adults. The long-term safety of daily TDF-FTC prophylaxis, including the effect on bone mineral density, remains unknown. (Funded by the Centers for Disease Control and Prevention and the National Institutes of Health; TDF2 ClinicalTrials.gov number, NCT00448669.).